| Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer. Its product portfolio includes active immunotherapy, monoclonal antibody, and small molecule product candidates to treat a range of cancers. The company's primary product candidate Provenge (sipuleucel-T) is an investigational active cellular immunotherapy, which completed Phase III clinical trials for the treatment of metastatic, androgen-independent prostate cancer. Dendreon also completed Phase I clinical trials for Neuvenge (lapuleucel-T), an investigational active cellular immunotherapy for the treatment of breast, ovarian, and colon cancers. In addition, its product candidates in research and development stages comprise immunotherapy targets, including Trp-p8 for lung, breast, prostate, and colon cancers; CEA for breast, lung, and colon cancers; CA-9 (MN) for kidney, colon, and cervical cancers; and monoclonal antibody ?Anti-Serine Protease? for multiple cancers. The company has collaborative agreements with Genentech, Inc. for the preclinical research, clinical development, and commercialization of products derived from trp-p8, an ion channel found in prostate cancer cells; and with Abgenix, Inc. for the discovery, development, and commercialization of human monoclonal antibodies against a membrane-bound serine protease implicated in various solid tumors, including breast and prostate cancer. Dendreon, formerly known as Activated Cell Therapy, Inc., was founded in 1992. The company is headquartered in Seattle, Washington. |
